Short-Term Erythropoietin Treatment Does Not Substantially Modulate Monocyte Transcriptomes of Patients with Combined Heart and Renal Failure

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Jie, Kim E ^a   van der Putten, Karien ^b,c   Wesseling, Sebastiaan ^a   Joles, Jaap A ^a   Bergevoet, Marloes W ^a   Pepers de Kort, Floor ^d   Doevendans, Pieter A ^a   Yasui, Yutaka ^e   Liu, Qi ^e   Verhaar, Marianne C ^a   Gaillard, Carlo A ^c,f   Braam, Branko ^e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d ServiceXS BV   (Netherlands)

^e UNIVERSITY OF ALBERTA   (Canada)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CD4 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; NEORECORMONROCHE PHA; RECOMBINANT ERYTHROPOIETIN; SPIRONOLACTONE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

AGED; ANEMIA; ARTICLE; CARDIORENAL SYNDROME; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; LOW DRUG DOSE; MALE; MONOCYTE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; RENAL ANEMIA; SHORT COURSE THERAPY;

AGED; ANEMIA; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD14; ANTIOXIDANTS; BIOSENSING TECHNIQUES; CARDIO-RENAL SYNDROME; CLUSTER ANALYSIS; DNA, COMPLEMENTARY; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION PROFILING; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; OXIDATIVE STRESS; RENAL INSUFFICIENCY; TRANSCRIPTOME;

EID: 84866017510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041339     Document Type: Article

References (47)

1. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, et al. (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113: 671-678.
2. Foley RN, Parfrey PS, Sarnak MJ, (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-119.
3. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B, (2005) The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26: 11-17.
4. Coulon S, Dussiot M, Grapton D, Maciel TT, Wang PH, et al. (2011) Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nature medicine 17: 1456-1465.
5. Jie KE, Verhaar MC, Cramer MJ, van der Putten K, Gaillard CA, et al. (2006) Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291: F932-944.
6. Lisowska KA, Debska-Slizien A, Bryl E, Rutkowski B, Witkowski JM, (2010) Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. Artificial organs 34: 654-662.
7. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, et al. (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52: 818-827.
8. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, et al. (2002) Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 40: 27-33.
9. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084.
10. Pfeffer MA, Burdmann EA, Chen YJ, Cooper ME, De Zeeuw D, et al. (2009) A trial of darbepoietin alpha in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032.
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098.
12. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, et al. (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798.
13. Chang YK, Choi DE, Na KR, Lee SJ, Suh KS, et al. (2009) Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects. J Urol 181: 1434-1443.
14. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007.
15. Ardigo D, Gaillard CA, Braam B, (2007) Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease. Clin Chem Lab Med 45: 1109-1120.
16. Chon H, Gaillard CA, van der Meijden BB, Dijstelbloem HM, Kraaijenhagen RJ, et al. (2004) Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension 43: 947-951.
17. Wibaut-Berlaimont V, Randi AM, Mandryko V, Lunnon MW, Haskard DO, et al. (2005) Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost 3: 677-685.
18. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U, (2004) Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119: 343-354.
19. Sprague AH, Khalil RA, (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol.
20. Rastmanesh MM, Bluyssen HA, Joles JA, Boer P, Willekes N, et al. (2008) Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. Eur J Pharmacol 593: 99-104.
21. Rastmanesh MM, Braam B, Joles JA, Boer P, Bluyssen HA, (2009) Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality. Eur J Pharmacol 602: 163-167.
22. Meier P, Antonov J, Zbinden R, Kuhn A, Zbinden S, et al. (2009) Non-invasive gene-expression-based detection of well-developed collateral function in individuals with and without coronary artery disease. Heart 95: 900-908.
23. van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, et al. (Prelim citation) Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. J Nephrol 23: 363-368.
24. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, et al. (2010) Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 12: 943-950.
25. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442.
26. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, et al. (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28: 2539-2550.
27. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032.
28. Blazejczyk M, Miron M, Nadon R (2007) FlexArray: A statistical data analysis software for gene expression microarrays. Montreal, Quebec, Canada.: Genome Quebec, Canada.
29. Baldi P, Long AD, (2001) A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17: 509-519.
30. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, et al. (2006) TM4 microarray software suite. Methods in enzymology 411: 134-193.
31. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
32. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, et al. (2003) SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4: 546-550.
33. Chon H, Verhaar MC, Koomans HA, Joles JA, Braam B, (2006) Role of circulating karyocytes in the initiation and progression of atherosclerosis. Hypertension 47: 803-810.
34. Maouche S, Poirier O, Godefroy T, Olaso R, Gut I, et al. (2008) Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells. BMC Genomics 9: 302.
35. Bluyssen HA, Rastmanesh MM, Tilburgs C, Jie K, Wesseling S, et al. (2010) IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol 299: C354-362.
36. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, et al. (2003) Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009-1016.
37. Lind L, (2003) Circulating markers of inflammation and atherosclerosis. Atherosclerosis 169: 203-214.
38. Malaponte G, Bevelacqua V, Fatuzzo P, Rapisarda F, Emmanuele G, et al. (2002) IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 17: 1964-1970.
39. Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TC, Moerland PD, et al. (2009) Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol 46: 177-185.
40. Strader CD, Fong TM, Tota MR, Underwood D, Dixon RA, (1994) Structure and function of G protein-coupled receptors. Annu Rev Biochem 63: 101-132.
41. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES, (2000) The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52: 595-638.
42. Jackson G, Gibbs CR, Davies MK, Lip GY, (2000) ABC of heart failure. Pathophysiology. BMJ 320: 167-170.
43. Koomans HA, Blankestijn PJ, Joles JA, (2004) Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 15: 524-537.
44. Fraser J, Nadeau J, Robertson D, Wood AJ, (1981) Regulation of human leukocyte beta receptors by endogenous catecholamines: relationship of leukocyte beta receptor density to the cardiac sensitivity to isoproterenol. J Clin Invest 67: 1777-1784.
45. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, et al. (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205-211.
46. Brodde OE, Daul A, (1986) Impaired regulation of alpha- and beta-adrenoceptor function in chronic renal insufficiency. Contrib Nephrol 50: 28-35.
47. Jie KE, van der Putten K, Bergevoet MW, Doevendans PA, Gaillard CA, et al. (2011) Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome. Heart 97: 60-65.